

Supplementary Table 1. Demographics and baseline characteristics for patients with CRVO or BRVO treated with ranibizumab injection or dexamethasone implant who had 24 months of follow-up data.

Characteristic	CRVO (<i>n</i> = 612)			BRVO (<i>n</i> = 800)		
	Ranibizumab injection (<i>n</i> = 539)	Dexamethasone implant (<i>n</i> = 73)	<i>P</i> -value	Ranibizumab injection (<i>n</i> = 713)	Dexamethasone implant (<i>n</i> = 87)	<i>P</i> -value
Age, mean, years, (SD)	72.5 (11.7)	70.1 (11.1)	0.094	73.4 (9.8)	72.8 (10.3)	0.604
Female, <i>n</i> (%)	296 (54.9)	37 (50.7)	0.496	407 (57.1)	36 (41.4)	0.005
Charlson–Deyo Comorbidity Index, mean (SD)	0.68 (1.13)	0.71 (1.11)	0.834	0.59 (1.06)	0.62 (0.98)	0.773
Payer type, <i>n</i> (%)						
Commercial	169 (31.4)	33 (45.2)	0.045	232 (32.5)	29 (33.3)	0.946
Medicare	364 (67.5)	39 (53.4)		476 (66.8)	58 (66.7)	
Medicaid	6 (1.1)	1 (1.4)		5 (0.7)	0 (0.0)	
US geographical region, <i>n</i> (%)						
Midwest	77 (14.3)	8 (11.0)	0.212	106 (14.9)	19 (21.8)	< 0.0001
Northeast	161 (29.9)	29 (39.7)		233 (32.7)	27 (31.0)	
West	230 (42.7)	24 (32.9)		301 (42.2)	19 (21.8)	
South	71 (13.2)	12 (16.4)		73 (10.2)	22 (25.3)	

BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; SD, standard deviation.